Abiopharma

🔍 Goodburn Giles Andrew (Executive)

Company: CONDUENT Inc (CNDT)

Report Date: 2026-04-01

Detailed Transactions and Holdings:

• Acquired 375,939 shares of Common Stock at $1.33 per share (Direct)
  Date: 2026-04-01 | Code: A | equity_swap_involved: 0 | shares_owned_after: 757,730.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 187,969 shares of Common Stock at $1.33 per share (Direct)
  Date: 2026-04-01 | Code: A | equity_swap_involved: 0 | shares_owned_after: 945,699.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: RSU Awards of restricted stock units ("RSUs") granted on April 1, 2026 that vest in equal amounts on December 31, 2026, December 31, 2027 and December 31, 2028. Each RSU converts to one share of Conduent Incorporated common stock ("Common Stock") upon vesting.
• F2: Award of performance restricted stock units ("PRSUs") that can only be settled in Common Stock. PRSUs have two vesting conditions - a service condition and a share price condition. The service condition requires continued employment through December 31, 2028 (the "Vesting Date"). The share price condition requires an average closing stock price over any 120 consecutive calendar day period during the measurement period of April 1, 2026 through December 31, 2028 (the "average closing price") of at least $2.50 per share. If an average closing price of $2.50/share is achieved, 25% is eligible to vest; if an average closing price of $3.00/share is achieved, 50% is eligible to vest; if an average closing price of $4.00/share is achieved, 75% is eligible to vest, and if an average closing price of $5.00/share or greater is achieved, 100% is eligible to vest, with linear interpolation between stock prices.
• F3: Vested shares are paid out within 60 days following the Vesting Date. Each PRSU converts to one share of Common Stock upon vesting.